Laurus Labs Limited has announced significant strategic developments, including a substantial investment in its joint venture and the appointment of two new independent directors. The company’s board of directors approved these decisions during a meeting held on April 30, 2026.
The board has authorised an investment of up to ₹82 crore (equivalent to EURO 9.8 million) in KRKA Pharma Private Limited, a joint venture of Laurus Labs. This investment aligns with the company’s strategic growth plans and long-term business objectives, with funds earmarked for KRKA’s capital expenditure plans, including setting up a manufacturing facility. The existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs will remain unchanged following this investment.
In addition to the investment, Laurus Labs has appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as independent directors for a term of five years, effective from July 2, 2026. Dr. Mande is a distinguished structural and computational biologist with a rich background in research and academia, having served as Director General of the Council of Scientific and Industrial Research (CSIR) and Secretary of the Department of Scientific and Industrial Research (DSIR), Government of India. Ms. Banerjee brings over three decades of experience in the financial services industry and has been recognised as a thought leader in wealth management.
The board also noted the retirement of Mrs. Aruna Bhinge as an independent director, effective from the close of business hours on July 6, 2026. Mrs. Bhinge completed her second term as an independent director, serving from July 7, 2021, to July 6, 2026.
Furthermore, the board approved the voluntary closure of Laurus Generics GmbH, a step-down wholly owned subsidiary in Germany. The closure is in accordance with applicable German laws and will not materially impact Laurus Labs’ financials, as Laurus Generics GmbH is not a material subsidiary and reported nil turnover for the year ending March 31, 2026.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).